Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 11/20 | 0.42 |
| ▸ | CTSL | P07711 | 4/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655936 | 0.80 | HDAC1 (0.54) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2643761 | 0.80 | EPHX2 (0.47) | HDAC3HDAC6MRGPRX4HDAC8EPHX2 | |
| SCHEMBL13813562 | 0.80 | HDAC1 (0.53) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2656900 | 0.80 | HDAC1 (0.50) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL2655937 | 0.79 | ALDH1A1 (0.57) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL14587226 | 0.78 | HDAC3 (0.51) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL8286119 | 0.76 | HDAC3 (0.49) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL2056117 | 0.76 | HDAC3 (0.49) | HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1956844 | 0.76 | HDAC3 (0.52) | HDAC1HDAC3HDAC2NCOR2CTSS | |
| SCHEMBL2056134 | 0.76 | HDAC3 (0.49) | HDAC1HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | HDAC1 2196/4885HDAC3 1032/4885HDAC2 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.